Ablynx: EURONEXT INTRODUCES SPOTLIGHT OPTIONS ON ABLYNX

           Ablynx: EURONEXT INTRODUCES SPOTLIGHT OPTIONS ON ABLYNX  REGULATED INFORMATION  GHENT, Belgium, 15 July 2014 -Ablynx [Euronext Brussels: ABLX] today announced that Euronext N.V. will introduce Spotlight Options on the shares of Ablynx (option trading symbol: ABY). The options will be available as of today on the derivatives market of Euronext Brussels.  Spotlight Options  are  a  special  segment  on  the  Amsterdam  and  Brussels  derivatives markets of Euronext,  dedicated to the  development of new  option  classes with  a short  maturity.  Through a  unique combination  of  Liquidity  Provider support  and dedicated  promotion by  Sponsoring Brokers,  underlying  assets with notable market  events or activity will  be put in the  spotlight.  The liquidity in these option classes will be supported by Susquehanna.  Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class  of therapeutic proteins based on  single-domain  antibody fragments, for  a range  of serious human  diseases in  the areas  of  inflammation, haematology,  oncology and  pulmonology. The  Company  currently  employs more than 300 people in its headquarters in Ghent, Belgium.  Dr Edwin Moses, Chief Executive Officer of Ablynx, commented: "Ablynx has made tremendous progress since  the initial public listing of  the  Company on Euronext  Brussels in  November 2007,  both on  an operational  and  financial level. Since its IPO, Ablynx  has developed into one of the  leading  biopharmaceutical companies in Europe  with more than 30  products in the  R&D  pipeline of which  seven are  in clinical development,  partnerships with  six  major pharma companies, a  strong cash position  and a free  float of 90%.  We  believe that  the  introduction of  Spotlight  Options will  offer  additional  investment and trading  possibilities, further increase  the liquidity of  our  shares and improve the visibility of the Company in the financial markets."  Vincent Van Dessel, Chief Executive Officer of Euronext Brussels, added: "We are pleased to announce the  introduction of Spotlight Options for  Ablynx  on Euronext Brussels,  providing institutional and  retail investors with  new  investment opportunities. The Ablynx Spotlight Option class will benefit  from  the growing interest in Belgian options we have seen over the past year."  About Ablynx  Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class  of therapeutic proteins based on  single-domain  antibody  fragments,  for  a  range  of  serious  human  diseases,   including  inflammation, haematology, oncology and pulmonary disease. Today, the  Company  has more than 30 programmes in  the pipeline and seven Nanobodies in  clinical  development. Ablynx  has  on-going  research  collaborations  and  significant  partnerships with major pharmaceutical companies including AbbVie,  Boehringer  Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.  For more information, please contact  Ablynx:  Dr Edwin Moses CEO t: +32 (0)9 262 00 07 m: +44 (0)7771 954 193 /  +32 (0)473 39 50 68 e: edwin.moses@ablynx.com  Marieke Vermeersch Associate Director Investor Relations t: +32 (0)9 262 00 82 m: +32 (0)479 49 06 03 e: marieke.vermeersch@ablynx.com Follow us on Twitter @AblynxABLX  Ablynx media relations Consilium Strategic Communications:  Mary-Jane Elliott, Amber Bielecka, Lindsey Neville t: +44 203 709 5700 e: ablynx@consilium-comms.com  Euronext Brussels:  Jean-Yves Daxhelet t: +32 2 213 13 03 e: jean-yves.daxhelet@interelgroup.com  pdf format of the press release  ------------------------------------------------------------------------------  This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Ablynx via Globenewswire HUG#1822671  
Press spacebar to pause and continue. Press esc to stop.